ArticleNature medicine2020
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors.
Open access · hybridAbstract read
In one paragraph
Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 212 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
212citing papers in PubMed, 2 pooled it
17.1field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
212 citing papers in PubMed, 2 syntheses or guidelines pooled it, 296 citations in OpenAlex.
- Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell strategies.Neurosurgical review · 2026Pooled it
- Locoregional delivery of CAR T cells in high-grade gliomas: a systematic analysis of safety, efficacy, and emerging biomarkers of response.Journal for immunotherapy of cancer · 2026Pooled it
- Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis.Oncogene · 2026Article
- Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial.Nature medicine · 2026Article
- mTORC1 activation induces B7-H3-dependent metabolic reprogramming in renal cell carcinoma (RCC).Oncogene · 2026Article
- CAR-T cell therapy: potential for paediatric brain tumours-an update.Journal of neuro-oncology · 2026Review
- Phase 1 study of intracranial T cell therapy with pemetrexed for refractory brain metastases and glioblastomas.Cell reports. Medicine · 2026Article
- Potent anti-tumor preclinical efficacy of B7-H3 CAR-T cells in H3G34-mutant, Diffuse Hemispheric Glioma.Neuro-oncology · 2026Article
- Anti-CAR Immunity Drives Acquired Therapeutic Resistance to GD2-CAR T Cell Therapy in Diffuse Midline Glioma.medRxiv : the preprint server for health sciences · 2026Article
- B7 homolog 3-targeted CAR-T cells secreting EGFR T-cell engagers for improved control of glioblastoma progression.Molecular biomedicine · 2026Article
- Targeting B7-H3 in patients with metastatic triple-negative breast cancer and brain metastases: an opportunity to "revive" immunotherapy as a treatment strategy?Journal for immunotherapy of cancer · 2026Article
- Paediatric Therapeutic Development Workshop on rhabdoid tumours.British journal of cancer · 2026Review
- Dual-modality imaging enables longitudinal biodistribution profiling of intracerebroventricular CAR-T therapy in orthotopic glioma.Cancer immunology, immunotherapy : CII · 2026Article
- Atypical Teratoid/Rhabdoid Tumor of the Lateral Ventricle: A Case Series and Experience with Molecular Subtyping-Guided Immunotherapy.Neurology international · 2026Article
- Pediatric Spinal Atypical Teratoid Rhabdoid Tumor: Recent Advances in Biology and Management Options.Cancers · 2026Review
- The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancer.Nature reviews. Clinical oncology · 2026Review
- Targeted therapies in pediatric oncology: A start.Molecular therapy. Oncology · 2026Review
- The promise of immunotherapy for central nervous system tumours.Nature reviews. Immunology · 2026Review
- Engineered nanovesicles as a DC vaccine to enhance the antitumor efficacy of CAR-T cells against solid tumors.Journal of nanobiotechnology · 2026Article
- Low-affinity binding of anti-B7-H3 clone MJ18 to murine B7-H3 fails to induce tumor regression.Scientific reports · 2026Article
152 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 12 institutions in 5 countries.
Johanna TheruvathDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Elena SotilloDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Christopher W MountDepartment of Neurology, Stanford University School of Medicine, Stanford, CA, USA.
Claus Moritz GraefDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Alberto DelaidelliDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Sabine HeitzenederDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Louai LabaniehDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Shaurya DhingraDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Amaury LerusteDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Robbie G MajznerDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Peng XuDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
Sabine MuellerDepartment of Neurology, University of California San Francisco, San Francisco, CA, USA.
Derek W YeciesDepartment of Neurosurgery, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-8534-4651
Martina A FinettiWolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.ORCID http://orcid.org/0000-0001-8173-1646
Daniel WilliamsonWolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
Pascal D JohannHopp Children's Cancer Center Heidelberg, Heidelberg, Germany.
Marcel KoolHopp Children's Cancer Center Heidelberg, Heidelberg, Germany.
Stefan PfisterHopp Children's Cancer Center Heidelberg, Heidelberg, Germany.
Martin HasselblattInstitute of Neuropathology, Münster University Hospital, Münster, Germany.
Michael C FrühwaldUniversity Children's Hospital Augsburg, Swabian Children's Cancer Center, Augsburg, Germany.
Olivier DelattreParis Sciences Lettres Research University, INSERM U830, Paris, France.
Didier SurdezParis Sciences Lettres Research University, INSERM U830, Paris, France.ORCID http://orcid.org/0000-0002-7118-7859
Franck BourdeautParis Sciences Lettres Research University, INSERM U830, Paris, France.
Stephanie PugetParis University, Necker-Enfants Malades Hospital, Department of Neurosurgery, Assistance Publique-Hôpitaux de Paris, Paris, France.
Sakina ZaidiParis Sciences Lettres Research University, INSERM U830, Paris, France.ORCID http://orcid.org/0000-0001-9128-0287
Siddhartha S MitraPediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID http://orcid.org/0000-0002-1829-7856
Samuel CheshierDivision of Pediatric Neurosurgery, Department of Neurosurgery, Primary Children's Hospital and Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
Poul H SorensenDepartment of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada.
Michelle MonjeDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-3547-237X
Crystal L MackallDepartment of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA. cmackall@stanford.edu.ORCID http://orcid.org/0000-0001-6323-4304
Stanford University · USInserm · FRGerman Cancer Research Center · DENewcastle University · GBCalifornia Institute for Regenerative Medicine · USHôpital Necker-Enfants Malades · FRPrimary Children's Hospital · USStanford Medicine · USUniversity Hospital Augsburg · DEUniversity Hospital Münster · DEUniversity of California, San Francisco · USUniversity of Colorado Anschutz Medical Campus · US
Funding
Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI Melinda L. Telli · 2007 to 2026
$71.4MStanford Neurosurgery Resident Research Education ProgramR25NS065741 · NINDS · STANFORD UNIVERSITY · PI HAYDEN GEPHART, MELANIE, PORTER, BRENDA ELAINE · 2009 to 2022
$2.0MNCI NIH HHS P30 CA124435NINDS NIH HHS R25 NS065741
Abstract
Atypical teratoid/rhabdoid tumors (ATRTs) typically arise in the central nervous system (CNS) of children under 3 years of age. Despite intensive multimodal therapy (surgery, chemotherapy and, if age permits, radiotherapy), median survival is 17 months
Indexed as
AdultAnimalsB7 AntigensBrainBrain NeoplasmsCancer VaccinesCells, CulturedChild, PreschoolFemaleFetusHumansImmunotherapy, AdoptiveInfantInjections, IntraventricularMiceMice, Inbred NODB7 AntigensCancer VaccinesCD276 protein, humanReceptors, Chimeric Antigen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.